A further cluster connects immune factors with epidemiology and interventions, bringing together terms such as “interleukin‐6” and “Mendelian randomization.” This pairing implies that researchers are using genetic approaches (e.g., variations in IL‐6 signaling as natural experiments) to infer causal links between inflammation and stroke, and are considering targeting such pathways in clinical interventions. This evidence concerns the gene IL6 and stroke disorder.